Anti-human GAD65 (U.Washington patent Anti-GAD65 Biosimilar) A4GALT N-cadherin

N-cadherin

Mutations associated with this gene cause autosomal recessive spastic paraplegia 13

Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis

the most common cause of senile dementia

osteoclasts and endothelial cells

Anti-human GAD65 (U.Washington patent Anti-GAD65 Biosimilar) A4GALT N-cadherinApplication ELISA, Bioactivity: FACS, Functional assay, Research in vivo Reactivity Human Target Target Name GAD65 Target Uniprot Q05329 Overview Catalog# BIO0807SM Product Name Anti human GAD65 (U. Washington patent Anti GAD65 Biosimilar) Specifications Conjugation None Clone# U. Washington patent Anti GAD65 Formulation 100 mM Pro Ac 20mM Arg pH 5. 0 Storage For long term storage, the produce should be stored at 20 or lower. Reconstitution Dissolve